Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if standard chemotherapy (gemcitabine and cisplatin)
given on a dose-dense treatment schedule (with less time between treatments) can help shrink
the tumor better than standard chemotherapy given on a standard treatment schedule before the
patient undergoes surgery for bladder cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
New York University University of North Carolina, Chapel Hill